Patents by Inventor Mark Andrew Paulik

Mark Andrew Paulik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150342897
    Abstract: Nanoparticles comprising biologically active peptides and poly(octylcyanoacrylate) as well as related subject matter is disclosed.
    Type: Application
    Filed: May 16, 2013
    Publication date: December 3, 2015
    Applicant: Glaxo Group Limited
    Inventors: Sean Matthew Cleveland, Mark Andrew Paulik, Stefan Salomon
  • Publication number: 20140349923
    Abstract: Compositions are disclosed which comprise one or more of the following; an anthocyanin, an oligosaccharide, a pectin, or a long-chain fatty acid. Such compositions are useful for treating diabetes or obesity.
    Type: Application
    Filed: January 14, 2013
    Publication date: November 27, 2014
    Inventors: Mark Andrew Paulik, Rebecca Jane Hodge
  • Publication number: 20140227264
    Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.
    Type: Application
    Filed: November 18, 2013
    Publication date: August 14, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventors: Bruce Hamilton, Christopher Herring, Mark Andrew Paulik
  • Publication number: 20120276098
    Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.
    Type: Application
    Filed: September 23, 2010
    Publication date: November 1, 2012
    Inventors: Bruce Hamilton, Christopher Herring, Mark Andrew Paulik
  • Publication number: 20120058116
    Abstract: The invention relates to combinations of FGFR1c antagonists with agonist peptides and provide dual targeting proteins which bind to FEFR1c comprising an antigen binding protein which is capable of binding to FGFR1c and which is linked to one or more agonist peptides, methods of making such constructs and uses thereof, particularly in treating obesity.
    Type: Application
    Filed: April 22, 2010
    Publication date: March 8, 2012
    Inventors: Andrew Beaton, Sean Matthew Cleveland, Gerald Wayne Gough, Mark Andrew Paulik
  • Patent number: 6983753
    Abstract: The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: January 10, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: James Martin Lenhard, Mark Andrew Paulik
  • Patent number: 6881584
    Abstract: The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: April 19, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: James Martin Lenhard, Mark Andrew Paulik